Fresh Learn

Oral antiviral candidate Paxlovid reduces COVID-19 risks by 89 percent.

Pfizer has announced its investigational novel COVID-19 oral antiviral candidate, Paxlovid™, significantly reduced hospitalization and death, based on an interim analysis of the Phase II/III EPIC-HR randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.

Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1.0 percent of patients who received Paxlovid were hospitalized through Day 28 following randomization with no deaths, compared to 6.7 percent of patients who received a placebo and were hospitalized or died. In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. Today’s news is a real game-changer in the global efforts to halt the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations.
source:europeanpharmaceuticalreview